Boston Scientific (NYSE: BSX) reported earnings on April 25. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), Boston Scientific missed slightly on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue dropped. Non-GAAP earnings per share grew. GAAP earnings per share dropped to a loss.

Gross margins increased, operating margins dropped, net margins dropped.

Revenue details
 Boston Scientific booked revenue of $1.76 billion. The 19 analysts polled by S&P Capital IQ expected revenue of $1.79 billion on the same basis. GAAP reported sales were 5.6% lower than the prior-year quarter's $1.87 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.10. The 21 earnings estimates compiled by S&P Capital IQ forecast $0.09 per share. Non-GAAP EPS of $0.10 for Q1 were 11% higher than the prior-year quarter's $0.09 per share. GAAP EPS were -$0.26 for Q1 compared to $0.08 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 64.8%, 100 basis points better than the prior-year quarter. Operating margin was 11.6%, 40 basis points worse than the prior-year quarter. Net margin was -20.1%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $1.79 billion. On the bottom line, the average EPS estimate is $0.09.

Next year's average estimate for revenue is $7.11 billion. The average EPS estimate is $0.41.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 747 members out of 933 rating the stock outperform, and 186 members rating it underperform. Among 178 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 160 give Boston Scientific a green thumbs-up, and 18 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Boston Scientific is hold, with an average price target of $7.58.

Is Boston Scientific the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.